# CAR-T

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, the Prime Minister of England, delayed the Brexit vote! The question becomes, what will be put forth next as a...

Prohost Biotech

Dec 28, 2018

Politics and the Market

Prohost Biotech

Dec 11, 2018

4

At the 60th American Society of Hematology (ASH) Annual Meeting CAR T is Still a Star With all the pessimistic views critics have sprayed around in the past few years about the cell therapy for can...

Celgene has important CAR T presentations at ASH

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, Celyad announced that the first patient has received an injection i...

Prohost Biotech

Dec 4, 2018

Why Celyad stock lost today instead of gaining on good news

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we keep reminding ourselves are undervalued. The outperformance unveiled the interred strength of firms s...

Prohost Biotech

Nov 30, 2018

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

CRISPR Gene Editing Beyond Bringing Cures to disease-causing genes, CRISPR gene editing technology can change the way diseases are being treated and treat diseases that have yet to find a treatment....

Prohost Biotech

Nov 8, 2018

CRISPR Therapeutics' new collaboration targeting Diabetes

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid scientific fundamentals, superior scientists and advanced technologies is what motivates us to pick fo...

Prohost Biotech

Sep 19, 2018

Outperforming, favorite, and undervalued biotech firms

Prohost Biotech

Sep 3, 2018

4

Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including solid tumors. Celyad announced its consolidated financial results for the six-month period ending...

Why Celyad’s stock gained $2.30 today

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If They Sell the Best of the Best Biotechnology Firms Only Because the Market Is Weird Even if one is scared...

Prohost Biotech

Aug 23, 2018

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several reasons, are a work in progress. The most two highlighted approaches that enable the immune...

Prohost Biotech

Apr 5, 2018

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

Prohost Biotech

Mar 21, 2018

1

Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which Celgene has agreed to acquire Juno. Celgene will pay $87 per share in cash, or a total of approximately...

Celgene Acquires Juno Therapeutics at $9 Billion or $87 a Share. Why Array is Trading Around $15 in Premarket Today.

Juno Therapeutics (JUNO) is one of the casualties that occurred during the 59 th American Society of Hematology (ASH) Annual Meeting. The stock experienced undeserved selloff except for the fact tha...

Prohost Biotech

Jan 22, 2018

Juno and Spark: On the Road Towards Ambitious Goals

Gilead Sciences (GILD ) has unsurprisingly agreed to acquire Cell Design Labs in a structured buy out valued for up to $567 million, including the shares of Cell Design Labs held by Kite, the CAR T fi...

Prohost Biotech

Dec 12, 2017

Gilead's New Acquisition: An Important Step Forward Toward Building a Superior Cancer Franchise

Prohost Biotech

Dec 8, 2017

2

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric rec...

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthr...

Prohost Biotech

Nov 21, 2017

New Breakthrough Immuno-Oncology Products

Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on Cancer Treatments... ...

Prohost Biotech

Oct 9, 2017

Gilead's Acquisition Effect on Other CAR-T Developers' Stocks

Prohost Biotech

Sep 4, 2017

7

The answer is, indeed, Gilead (GILD) and its CAR T drug approval will be for non-Hodgkin lymphoma (NHL). This is true, as in May, the FDA has accepted for priority review Kite Pharma’s Biologics Licen...

The FDA Granted Novartis a Historical First CAR-T Approval for Leukemia. Can You Guess Who Will Be Granted the Second Historical CAR-T Approval?

CRISPR Therapeutics (CRSP) and Massachusetts General Hospital Cancer Center (MGHCC) have entered into a two-year research collaboration and license option agreement to develop Novel T cell therapies...

Prohost Biotech

Aug 31, 2017

CRISPR Therapeutics' Worthwhile Deal

Prohost Biotech

Aug 28, 2017

2

When what you predicted, preached, and wished are realized, this is good news. Today’s news is bringing all Prohost predictions into realization, Yes, Kite (KITE) is on its way to be acquired by Gile...

Gilead to Acquire Kite and Juno Stock Rallied Too

THE WEEK IN REVIEW Wall Street As we said in yesterday’s article posted under Today’s Highlights, stocks can plummet at any time, regardless of whether they have the best or the worst grades for their...

Prohost Biotech

Aug 28, 2017

The STAR of the Week

Prohost Biotech

Aug 20, 2017